M Ambrosini, B Rousseau, P Manca, O Artz, A Marabelle, T André, G Maddalena, G Mazzoli, R Intini, R Cohen, A Cercek, N H Segal, L Saltz, A M Varghese, R Yaeger, M Nusrat, Z Goldberg, G Y Ku, I El Dika, O Margalit, A Grinshpun, P Kasi, R Schilsky, A Lutfi, E Shacham-Shmueli, M Khan Afghan, L Weiss, C B Westphalen, V Conca, B Decker, G Randon, E Elez, M Fakih, A B Schrock, C Cremolini, P Jayachandran, M J Overman, S Lonardi, F Pietrantonio
BACKGROUND: POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific data about the activity and efficacy of immune checkpoint inhibitors (ICIs) in POLE/D1pd mCRC are lacking and it is unknown whether outcomes may be different from mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) mCRCs treated with ICIs. PATIENTS AND METHODS: In this global study, we collected 27 patients with mCRC harboring POLE/D1 mutations leading to proofreading deficiency and treated with anti-programmed cell death-ligand 1 alone +/- anti-cytotoxic T-lymphocyte antigen-4 agents...
May 3, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology